NPC
TCRT icon

National Planning Corporation’s Alaunos Therapeutics TCRT Stock Holding History

National Planning Corporation’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-225
Closed -$207K – 548
2017
Q3 		$207K Hold
225
– – 0.02% 625
2017
Q2 		$208K Buy
225
+13
+6% +$12.7K 0.02% 669
2017
Q1 		$201K Sell
212
-2
-0.9% -$1.86K 0.02% 643
2016
Q4 		$204K Buy
214
+17
+9% +$15.3K 0.02% 622
2016
Q3 		$171K Buy
197
+17
+9% +$13.7K 0.01% 600
2016
Q2 		$132K Buy
180
+20
+13% +$21.8K 0.01% 632
2016
Q1 		$168K Buy
160
+31
+24% +$31.7K 0.01% 593
2015
Q4 		$99K Buy
129
+53
+70% +$87.7K 0.01% 690
2015
Q3 		$152K Buy
+76
New +$125K 0.01% 582
2015
Q1 		– Sell
-3
Closed -$2.51K – 1901
2014
Q4 		$2.51K Buy
+3
New +$1.59K ﹤0.01% 2529

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Planning Corporation's TCRT Position: Q4 2017 in Review

National Planning Corporation sold out of Alaunos Therapeutics (TCRT) in Q4 2017, closing a stake of 225 shares — an estimated $207K sold.

National Planning Corporation first reported a position in TCRT in Q4 2014 and held it in 10 quarters. The position peaked at $208K in Q2 2017. 128 funds tracked by Wall St. Rank hold TCRT as of Q4 2017.

  • National Planning Corporation reported no remaining Alaunos Therapeutics position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 225 Alaunos Therapeutics shares in Q4 2017, an estimated $207K.
  • National Planning Corporation first reported a position in Alaunos Therapeutics in Q4 2014 and held it in 10 quarters.
  • National Planning Corporation's Alaunos Therapeutics position peaked at $208K in Q2 2017.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.